Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 101–200 of 1,000
van Himbergen, T. M., Matthan, N. R., Resteghini, N. A., Otokozawa, S., Ai, M., Stein, E. A., Jones, P. H., & Schaefer, E. J. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p800042-jlr200 · Cited by 109
Self-citationThe Importance of Clinical Trial Data Sharing: Toward More Open Science
Ross, J. S., Lehman, R., & Gross, C. P. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.965798 · Cited by 104
Management of Extracranial Carotid Artery Disease
Ooi, Y. C., & Gonzalez, N. R. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.09.001 · Cited by 111
“The ARBITER-2 and Effect of Combination Ezetimibe and High-Dose versus Simvastatin Alone on the Atherosclerosis Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) studies showed that the addition of extended-release niacin and ezetimibe, respectively, to statin therapy did not affect progres…”
BackgroundSilbernagel, G., Fauler, G., Hoffmann, M. M., Lütjohann, D., Winkelmann, B. R., Boehm, B. O., & März, W. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p002899 · Cited by 101
Kastelein, J. J. P., Besseling, J., Shah, S., Bergeron, J., Langslet, G., Hovingh, G. K., Al‐Saady, N., Koeijvoets, M., Hunter, J. A., Johnson‐Levonas, A. O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62115-2 · Cited by 102
Self-citationCombined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100
Familial hypercholesterolemia: A review
Varghese, M. J. (2014) · Annals of Pediatric Cardiology · doi:10.4103/0974-2069.132478 · Cited by 118
“[57,58] However, the initial fervor over their use was dampened by the largest prospective trial (ENHANCE trial) on cholesterol absorption inhibitors until this time, which demonstrated that ezetimibe added to high dose simvastatin failed to lessen carotid intima medial thickness in spite of a significant diminution i…”
BackgroundHou, R., & Goldberg, A. C. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.007 · Cited by 106
“A recently reported study comparing the effect of the combination of ezetimibe plus simvastatin versus simvastatin alone on the progression of carotid intima medial thickness (cIMT) in patients who had familial hypercholesterolemia did not show a significant difference between the two groups.(62) The study may not hav…”
ResultFibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Kim, N. H., & Kim, S. G. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0001 · Cited by 104
Silbernagel, G., Fauler, G., Renner, W., Landl, E. M., Hoffmann, M. M., Winkelmann, B. R., Boehm, B. O., & März, W. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p800013-jlr200 · Cited by 96
Blazing, M. A., Giugliano, R. P., Cannon, C. P., Musliner, T. A., Tershakovec, A. M., White, J. A., Reist, C., McCagg, A., Braunwald, E., & Califf, R. M. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.05.004 · Cited by 94
Goldberger, Z. D., Valle, J. A., Dandekar, V. K., Chan, P. S.-F., Ko, D. T., & Nallamothu, B. K. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.06.029 · Cited by 106
Dyslipidemia in diabetes mellitus and cardiovascular disease
Warraich, H. J., & Rana, J. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000120 · Cited by 103
Guidelines for the Diagnosis and Treatment of Pediatric Familial Hypercholesterolemia 2022
Harada‐Shiba, M., Ohtake, A., Sugiyama, D., Tada, H., Dobashi, K., Matsuki, K., Minamino, T., Yamashita, S., & Yamamoto, Y. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.cr006 · Cited by 97
Does ENHANCE Diminish Confidence in Lowering LDL or in Ezetimibe?
Brown, B. G., & Taylor, A. J. (2008) · New England Journal of Medicine · doi:10.1056/nejme0801608 · Cited by 102
LDL Cholesterol: The Lower the Better
Martin, S. S., Blumenthal, R. S., & Miller, M. J. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.01.009 · Cited by 99
Three-dimensional Ultrasound Quantification of Intensive Statin Treatment of Carotid Atherosclerosis
Krasinski, A., Chiu, B. C. Y., Spence, J. D., Fenster, A., & Párraga, G. (2009) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2009.05.017 · Cited by 105
Zhang, M., Liu, Y., Xu, M., Zhang, L., Liu, Y., Liu, X., Zhao, Y., Zhu, F., Xu, R., Ou, Z.-H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41118-z · Cited by 92
Pearson, T. A., Ballantyne, C. M., Veltri, E. P., Shah, A. K., Bird, S. R., Lin, J., Rosenberg, E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.090 · Cited by 94
Self-citationUse of Ezetimibe in the United States and Canada
Jackevicius, C. A., Tu, J. V., Ross, J. S., Ko, D. T., & Krumholz, H. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa0801461 · Cited by 95
Higgins, P., Walters, M. R., Murray, H. M., McArthur, K., McConnachie, A., Lees, K. R., & Dawson, J. (2014) · Heart · doi:10.1136/heartjnl-2014-305683 · Cited by 96
Rundek, T., Blanton, S. H., Bartels, S., Dong, C., Raval, A. P., Demmer, R. T., Cabral, D., Elkind, M. S. V., Sacco, R. L., & Desvarieux, M. (2013) · Stroke · doi:10.1161/strokeaha.111.000745 · Cited by 90
“any reduction of cIMT, despite an obvious lowering effect on LDL-C.(35) Numerous lipid-levering interventional clinical trials have used cIMT as a surrogate measure of atherosclerosis with inconsistent and often conflicting results.”
Carotid intima-media thickness measurements: Techniques and clinical relevance
Coll, B., & Feinstein, S. B. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-008-0068-1 · Cited by 90
Duivenvoorden, R., de Groot, E., Elsen, B. M., Laméris, J. S., van der Geest, R. J., Stroes, E. S., Kastelein, J. J. P., & Nederveen, A. J. (2009) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.108.788059 · Cited by 89
Self-citationKovárník, T., Mintz, G. S., Skalická, H., Král, A., Horák, J., Škulec, R., Uhrová, J., Pavel Martasek, E., Downe, R., Wahle, A., et al. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0730 · Cited by 90
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88
Identification of Novel Inhibitors of Dietary Lipid Absorption Using Zebrafish
Clifton, J. D., Lucumi, E., Myers, M. C., Napper, A. D., Hama, K., Farber, S. A., Smith, A. B., Huryn, D. M., Diamond, S. L., & Pack, M. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012386 · Cited by 88
Masoura, C., Pitsavos, C. E., Aznaouridis, K. A., Skoumas, I., Vlachopoulos, C. V., & Stefanadis, C. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.008 · Cited by 99
Califf, R. M., Lokhnygina, Y. V., Cannon, C. P., Stepanavage, M. E., McCabe, C. H., Musliner, T. A., Pasternak, R. C., Blazing, M. A., Giugliano, R. P., Harrington, R. A., et al. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.03.004 · Cited by 89
Bots, M. L., Evans, G. W., Tegeler, C. H., & Meijer, R. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.173500 · Cited by 96
Self-citationPoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
“Published RCTs on ezetimibe have demonstrated a high lipid-lowering efficacy and a beneficial safety profile of combination therapy in a group of patients with primary hypercholesterolaemia [60], kidney failure [61], type 2 diabetes [62], metabolic syndrome [63], high CV risk [64] and acute coronary syndrome [44].”
BackgroundConsensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 102
“In the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, the addition of ezetimibe to statin therapy did not significantly change CIMT compared to statin monotherapy, despite a >50 mg/dl lowering of LDL in the combination therapy group.(241)”
BackgroundThe Antithrombotic Effects of Statins
Owens, A. P., & Mackman, N. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-051812-145304 · Cited by 86
Kusters, D. M., Caceres, M., Mauricio Coll, B., Cuffie, C. A., Gagné, C., Jacobson, M. S., Kwiterovich, P. O., Lee, R., Lowe, R. S., Massaad, R., et al. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.02.043 · Cited by 85
Self-citationMipomersen, an antisense apolipoprotein B synthesis inhibitor
Bell, D. A., Hooper, A. J., & Burnett, J. R. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.547471 · Cited by 84
“However, the benefits of ezetimibe on cardiovascular and all-causes mortality are less clear [13,14].”
BackgroundLauridsen, B. K., Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv108 · Cited by 81
Simvastatin vs Therapeutic Lifestyle Changes and Supplements: Randomized Primary Prevention Trial
Becker, D. J., Gordon, R. Y., Morris, P. B., Yorko, J., Gordon, Y. J., Li, M., & Iqbal, N. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.758 · Cited by 91
WEINTRAUB, H. S. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.07.041 · Cited by 90
“While the lipid-lowering efficacy and safety of the cholesterol absorption inhibitor ezetimibe were established through a range of clinical studies including investigations of combination use with statins [14], controversy emerged with regard to ezetimibe’s vascular and clinical benefit due to the disappointing result…”
BackgroundYu, J., Shah, B. M., Ip, E. J., & Chan, J. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.102 · Cited by 88
Dyslipidemia and its Treatment in HIV Infection.
Grünfeld, C. (2010) · PubMed · Cited by 82
Promoting Transparency in Pharmaceutical Industry–Sponsored Research
Ross, J. S., Gross, C. P., & Krumholz, H. M. (2011) · American Journal of Public Health · doi:10.2105/ajph.2011.300187 · Cited by 85
Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Self-citationLipids, lipid modifying agents and cardiovascular risk: a review of the evidence
Preiss, D., & Sattar, N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03490.x · Cited by 82
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline
West, A. M., Anderson, J. D., Meyer, C. H., Epstein, F. H., Wang, H., Hagspiel, K. D., Berr, S. S., Harthun, N. L., DiMaria, J. M., Hunter, J. R., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.005 · Cited by 80
Ezetimibe: an update on its clinical usefulness in specific patient groups
Hammersley, D. J., & Signy, M. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622316672544 · Cited by 83
Sharma, M., Ansari, M. T., Abou-Setta, A. M., Soares-Weiser, K., Ooi, T. C., Sears, M., Yazdi, F., Tsertsvadze, A., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-9-200911030-00144 · Cited by 79
“…et al, 2002 (17) Kosoglou et al, 2002 (52) Patel and Hughes, 2006 (84) Berthold et al, 2006 (87) Chenot et al, 2007 (91) Shankar et al, 2007 (93) Kastelein et al, 2008 (99) Roeters van Lennep et al, 2008 (108) Gouni-Berthold et al, 2008 (109) Dobs et al, 2003 (21) Grundy et al, 2005 (37)…”
Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon, R. D., Barry, A. R., & Pearson, G. J. (2016) · Canadian Family Physician · Cited by 106
The Vytorin on Carotid Intima‐Media Thickness and Overall Arterial Rigidity (VYCTOR) Study
Meaney, A., Ceballos, G., Asbun, J., Solache, G., Mendoza, E., Vela, A., & Meaney, E. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337011 · Cited by 75
Stramba‐Badiale, M. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq094 · Cited by 87
Gómez‐Garré, D., Muñoz‐Pacheco, P., Gonzalez-Rubio, M., Aragoncillo, P., Granados, R., & Fernández‐Cruz, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00091.x · Cited by 81
“Only rabbits treated with ezetimibe plus simvastatin normalized CRP plasma levels.”
BackgroundResultInfluentialNieminen, T., Kähönen, M., Viiri, L. E., Grönroos, P., & Lehtimäki, T. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1475 · Cited by 77
MR plaque imaging of the carotid artery
Watanabe, Y., & Nagayama, M. (2010) · Neuroradiology · doi:10.1007/s00234-010-0663-z · Cited by 82
Gudzune, K. A., Monroe, A. K., Sharma, R., Ranasinghe, P. D., Chelladurai, Y., & Robinson, K. A. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2526 · Cited by 69
ACCF/AHA/AMA–PCPI 2011 Performance Measures for Adults With Coronary Artery Disease and Hypertension
Drozda, J. P., Messer, J. V., Spertus, J. A., Abramowitz, B. M., Alexander, K. P., Beam, C. T., Bonow, R. O., Burkiewicz, J. S., Crouch, M., Goff, D. C., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.002 · Cited by 74
I Diretriz Brasileira de Hipercolesterolemia Familiar (HF)
Santos, R., Gagliardi, A., Xavier, H. T., Filho, A. C., Araújo, D., Cesena, F., Alves, R., Pereira, A., Lotemberg, A., Chacra, A., et al. (2012) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20120202 · Cited by 99
Form to function: current and future roles for atherosclerosis imaging in drug development
Lindsay, A. C., & Choudhury, R. P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2588 · Cited by 79
“In patients with familial hypercholesterolaemia, who were treated with simvastatin 80 mg daily, the addition of the cholesterol absorption inhibitor ezetimibe further lowered low-density lipoprotein (LDL) cholesterol by ∼27% versus placeb”
BackgroundSafety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia
Almutairi, F., Peterson, T. C., Molinari, M., Walsh, M. J., Alwayn, I., & Peltekian, K. M. (2009) · Liver Transplantation · doi:10.1002/lt.21710 · Cited by 73
“Recently, the results of the ENHANCE study were published, confirming the safety of the combination of ezetimibe and simvastatin in further lowering LDL cholesterol.(22) However, the combination was no more effective in reducing atherosclerosis than simvastatin by itself.”
ResultAmerican Diabetes Association Indications for Statins in Diabetes
Eldor, R., & Raz, I. (2009) · Diabetes Care · doi:10.2337/dc09-s345 · Cited by 71
“5% reduction in LDL levels in the ezetimibe-treated cohort) (13).”
BackgroundKlose, G., Laufs, U., März, W., & Windler, E. E. T. (2014) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2014.0523 · Cited by 88
Insight into recent reforms and initiatives in Austria: implications for key stakeholders
Godman, B., Bucsics, A., Burkhardt, T. H., Haycox, A. R., Seyfried, H., & Wieninger, P. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.4.357 · Cited by 78
Henningsen, K. M. A., Therkelsen, S. K., Brüünsgaard, H., Krabbe, K. S., Pedersen, B. K., & Svendsen, J. H. (2009) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802676848 · Cited by 71
The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
Lathia, C., Amakye, D. D., Dai, W., Girman, C. J., Madani, S., Mayne, J. T., MacCarthy, P., Pertel, P. E., SEMAN, L. J., Stoch, A., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.69 · Cited by 72
Venous and arterial disease in inflammatory bowel disease
Tan, V. P. Y., Chung, A., Yan, B. P., & Gibson, P. R. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12260 · Cited by 70
Risk Factor Management to Prevent First Stroke
Rundek, T., & Sacco, R. L. (2008) · Neurologic Clinics · doi:10.1016/j.ncl.2008.09.001 · Cited by 83
“However, the Enhance study (Effect of Combination Ezetimibe and High-Dose Simvastatin Versus Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) showed no difference in the progression of carotid atherosclerosis between ezetimibe and simvastatin versus simvasta…”
A systematic review of the time course of atherosclerotic plaque regression
Noyes, A. M., & Thompson, P. D. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.007 · Cited by 76
Kim, K., Kim, S., Yoon, Y. W., Rha, S., Hong, S. J., Kwak, C. H., Kim, W., Nam, C., Rhee, M., Park, T., et al. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12213 · Cited by 73
“The main exclusion criteria included (1) history of significant statin and/or ezetimibe- induced myopathy or rhabdomyolysis; (2) history of serious hypersensitivity reaction to rosuvastatin or ezetimibe; (3) history of unstable angina, myocardial infarction, myocardial revascularization, coronary artery bypass surgery…”
BackgroundMcGinn, D., Godman, B., Lonsdale, J., Way, R., Wettermark, B., & Haycox, A. R. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.09.73 · Cited by 84
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
Burnett, J., Bell, Hooper, & Watts (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s28581 · Cited by 64
“Ezetimibe has been shown to effectively lower LDL-cholesterol when added to a statin, however, this did not lead to an improvement in carotid intima-media thickness over a 2-year follow-up period.(32) LDL apheresis is a radical form of treatment for FH that entails the extracorporeal removal of apoB-containing lipopro…”
Communicating Uncertainties About Prescription Drugs to the Public: A National Randomized Trial
Schwartz, L. M., & Woloshin, S. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.396 · Cited by 69
Imaging Biomarkers in Atherosclerosis Trials
Tardif, J., Lesage, F., Harel, F., Roméo, P., & Pressacco, J. (2011) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.110.962001 · Cited by 73
Berneis, K. K., Rizzo, M., Berthold, H. K., Spinas, G. A., Krone, W., & Gouni‐Berthold, I. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq181 · Cited by 69
“HDL cholesterol (mg/dL) 64 (15) 64 (13) 61 (14) 65 (18)”
Ballantyne, C. M., Gellis, L., Tardif, J.-C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., et al. (2026) · JAMA · doi:10.1001/jama.2025.20620 · Cited by 68
Self-citationHirsch, L. J. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.9.811 · Cited by 78
Elis, A., Zhou, R., & Stein, E. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.027 · Cited by 73
Self-citationMendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 68
Atherosclerosis: lessons from LXR and the intestine
Bonamassa, B., & Moschetta, A. (2012) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2012.10.004 · Cited by 75
Ezetimibe Treatment of Pediatric Patients with Hypercholesterolemia
Clauss, S. B., Wai, K., Kavey, R.-E. W., & KUEHL, K. S. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.12.044 · Cited by 67
Brown, J., & Yu, L. (2009) · Immunology‚ Endocrine & Metabolic Agents in Medicinal Chemistry · doi:10.2174/187152209788009797 · Cited by 63
“Therefore, four highly publicized randomized, double-blind, clinical outcomes trials (ENHANCE = Ezetimibe and Simvastatin in Hypercholerolemia Enhances Atherosclerosis Regression study; SEAS = Simvastatin and Ezetimibe in Aortic Stenosis study; SHARP = Study of Heart and Renal Protection; and IMPROVE IT = the Improved…”
BackgroundClinical and Research Applications of Carotid Intima-Media Thickness
Sharma, K., Blaha, M. J., Blumenthal, R. S., & Musunuru, K. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.01.020 · Cited by 75
Lewek, J., Niedziela, J. T., Desperak, P., Dyrbuś, K., Osadnik, T., Jankowski, P., Witkowski, A., Bielecka-Dabrowa, A. M., Dudek, D., Gierlotka, M. J., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030414 · Cited by 69
Masuda, J., Tanigawa, T., Yamada, T., Nishimura, Y., Sasou, T., Nakata, T., Sawai, T., Fujimoto, N., Dohi, K., Miyahara, M., et al. (2015) · International Heart Journal · doi:10.1536/ihj.14-311 · Cited by 66
Pećin, I., Hartgers, M. L., Hovingh, G. K., Dent, R. E., & Reiner, Ž. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317717346 · Cited by 70
“The clinical efficacy of ezetimibe was questioned following results from the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial, which showed that the addition of ezetimibe to simvastatin led to a reduction in LDL-cholesterol, but not to a reduction in carotid intima–…”
ResultHoogeveen, R. M., Nahrendorf, M., Riksen, N. P., Netea, M. G., de Winther, M. P. J., Lutgens, E., Nordestgaard, B. G., Neidhart, M., Stroes, E. S. G., Catapano, A. L., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx581 · Cited by 69
Self-citationMani, V., Muntner, P., Gidding, S. S., Aguiar, S., Aidi, H. E., Weinshelbaum, K. B., Taniguchi, H., van der Geest, R. J., Reiber, J. H. C., Bansilal, S., et al. (2009) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-11-10 · Cited by 65
“Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) clinical trial recently compared the mean change in the intima-media thickness (IMT) measured at three sites in the carotid arteries between patients with heterozygous familial hypercholesterolemia treated wit…”
Carotid intima–media thickness and the prediction of vascular events
Robertson, C. M., Gerry, F., Fowkes, R., & Price, J. F. (2012) · Vascular Medicine · doi:10.1177/1358863x12445103 · Cited by 69
Zoppini, G., Targher, G., Chonchol, M., Perrone, F., Lippi, G., & Muggeo, M. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.11.003 · Cited by 67
Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects
Baudrand, R. F., Pojoga, L. H., Vaidya, A., Garza, A., Vöhringer, P. A., Jeunemaître, X., Hopkins, P. N., Yao, T. M., Williams, J. S., Adler, G. K., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016759 · Cited by 61
“Interestingly, these statin effects are not consistently observed with low-cholesterol diets,(14) nor with other lipid-lowering medications such as niacin, ezetimibe, cholesterol ester transfer protein inhibitors, or fibrates.(11,15,16) To date, the multifactorial mechanisms involved in statin’s antithrombotic, anti-i…”
BackgroundScreening for Subclinical Coronary Artery Disease Measuring Carotid Intima Media Thickness
Nguyen-Thanh, H.-T., & Benzaquen, B. S. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.07.005 · Cited by 65
Paquette, M., Brisson, D., Dufour, R., Khoury, É., Gaudet, D., & Baass, A. W. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.07.008 · Cited by 62
Self-citationLipoprotein metabolism in familial hypercholesterolemia
Chemello, K., García‐Nafría, J., Gallo, A., Martín, C., Lambert, G. C., & Blom, D. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100062 · Cited by 65
Migrino, R. Q., Bowers, M. R., Harmann, L. M., Prost, R. W., & LaDisa, J. F. (2011) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-13-37 · Cited by 59
“The average of the mean posterior IMT of the common carotid/bifurcation/internal carotid artery in 10-mm segments was used for analysis, similar to ENHANCE trial method [23].”
BackgroundMethodInfluentialCholesterol Lowering and Ezetimibe
Drazen, J. M., Jarcho, J. A., Morrissey, S., & Curfman, G. (2008) · New England Journal of Medicine · doi:10.1056/nejme0801842 · Cited by 59
Wohl, D. A., Waters, D., Simpson, R. J., Richard, S., Schnell, A., Napravnik, S., Keys, J., Eron, J. J., & Hsue, P. (2008) · Clinical Infectious Diseases · doi:10.1086/592116 · Cited by 57
“vastatin alone in patients with heterozygous familial hypercholesterolemia showed no improvement in carotid intimal thickening with the addition of ezetimibe [20].”
BackgroundLappegård, K. T., Pop‐Purceleanu, M., van Heerde, W. L., Sexton, J., Tendolkar, I., & Pop, G. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-78 · Cited by 58
Minhas, R., Humphries, S. E., Qureshi, N., & Neil, H. A. W. (2009) · Heart · doi:10.1136/hrt.2008.162909 · Cited by 58
“Recommendations on the sequencing of second-line drugs were based on indirect evidence and clinical experience, as no head-to-head trials were identified. The GDG reviewed the ENHANCE study,”
Miname, M. H., & Santos, R. D. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.003 · Cited by 61
VersorgungsLeitlinie, N. (2011) · Cited by 58
Dyslipidemia in Youth with Diabetes: To Treat or Not to Treat?
Maahs, D. M., Wadwa, R. P., Bishop, F. K., Daniels, S. R., Rewers, M., & KLINGENSMITH, G. J. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.062 · Cited by 62
“Whether ezetimibe has a role in pediatrics is under investigation, however the ENHANCE trial recently reported no additional benefit in carotid IMT with ezetimibe added to simvastatin compared with simvastatin alone in hypercholesterolemic adults (mean LDLc>300mg/dl at baseline), although it did significantly decrease…”
BackgroundToth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Self-citationGenesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection
Badimón, J. J., Ibáñez, B., & Cimmino, G. (2009) · Cerebrovascular Diseases · doi:10.1159/000200440 · Cited by 56
“Noninvasive ultrasound measurements of carotid and aortic artery wall thickness are an accurate noninvasive technique that permits correlation with clinical events. Intima-media thickening (IMT) is a reliable parameter for serial measurements of carotid atherosclerotic plaque evolvement, and is considered a marker of…”
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.